LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Search

Becton Dickinson and Co

Geschlossen

Branche Gesundheitswesen

232.6 -0.17

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

232.41

Max

233.91

Schlüsselkennzahlen

By Trading Economics

Einkommen

-50M

487M

Verkäufe

10M

5.1B

KGV

Branchendurchschnitt

50.04

103.001

EPS

3.5

Gewinnspanne

9.625

Angestellte

73,000

EBITDA

-124M

1.2B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+20.64 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Nov. 2024

Nächste Dividendenausschüttung

30. Sept. 2024

Nächstes Ex-Dividendendatum

9. Sept. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

70B

Vorheriger Eröffnungskurs

232.77

Vorheriger Schlusskurs

232.6

Nachrichtenstimmung

By Acuity

9%

91%

8 / 365 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Becton Dickinson and Co Chart

Ähnliche Nachrichten

1. Aug. 2024, 11:08 UTC

Ergebnisse

Becton 3Q Adjusted Earnings Top Views But International Sales Weigh on FY24 Outlook

3. Juni 2024, 11:18 UTC

Akquisitionen, Fusionen, Übernahmen

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

2. Mai 2024, 11:07 UTC

Ergebnisse

Becton Dickinson Shakes Up 2024 Outlook After Growing 2Q Sales, Earnings

1. Aug. 2024, 10:37 UTC

Ergebnisse

Becton Dickinson Now Sees FY24 Revenue About $20.1B; Had Seen $20.1B-$20.3B >BDX

1. Aug. 2024, 10:35 UTC

Ergebnisse

Becton Dickinson Sees FY24 Revenue Up About 3.7%, Organic Revenue Up 5%-5.25% >BDX

1. Aug. 2024, 10:35 UTC

Ergebnisse

Becton Dickinson Sees FY24 Adj EPS $13.05-Adj EPS $13.15 >BDX

1. Aug. 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 3Q EPS $1.68 >BDX

1. Aug. 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 3Q Net $487M >BDX

1. Aug. 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 3Q Adj EPS $3.50 >BDX

1. Aug. 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 3Q Rev $5B >BDX

4. Juni 2024, 17:26 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3. Juni 2024, 15:30 UTC

Heiße Aktien

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3. Juni 2024, 13:26 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3. Juni 2024, 12:25 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

3. Juni 2024, 11:03 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2B in Cash

3. Juni 2024, 10:40 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences To Sell Its Critical Care Product Group For $4.2 Billion To Becton Dickinson -- MarketWatch

3. Juni 2024, 10:32 UTC

Akquisitionen, Fusionen, Übernahmen

Becton Dickinson: Acquired Business Has About 4,500 Employees >BDX EW

3. Juni 2024, 10:31 UTC

Akquisitionen, Fusionen, Übernahmen

Becton Dickinson: Acquired Business Generated More Than $900 Million Revenue in 2023 >BDX

3. Juni 2024, 10:31 UTC

Akquisitionen, Fusionen, Übernahmen

Becton Dickinson: Deal Expands Portfolio of Smart Connected Care Solutions >BDX EW

3. Juni 2024, 10:30 UTC

Akquisitionen, Fusionen, Übernahmen

Becton Dickinson to Buy Edwards Lifesciences Critical Care Product Group for $4.2 Billion >BDX EW

3. Juni 2024, 10:30 UTC

Akquisitionen, Fusionen, Übernahmen

BD To Acquire Edwards Lifesciences' Critical Care Product Group For $4.2 Billion To Expand Smart Connected Care Solutions And Become An Advanced Monitoring Technology Leader >BDX EW

2. Mai 2024, 10:35 UTC

Ergebnisse

Becton Dickinson Had Seen FY24 Adjusted EPS $12.82-$13.06 >BDX

2. Mai 2024, 10:34 UTC

Ergebnisse

Becton Dickinson Raises FY24 View To Adj EPS $12.95-Adj EPS $13.15 >BDX

2. Mai 2024, 10:34 UTC

Ergebnisse

Becton Dickinson Still Sees FY24 Organic Revenue Growth of 5.5%-6.25% >BDX

2. Mai 2024, 10:33 UTC

Ergebnisse

Becton Dickinson Had Seen FY24 Revenue $20.2B-$20.4B >BDX

2. Mai 2024, 10:33 UTC

Ergebnisse

Becton Dickinson Cuts FY24 View To Rev $20.1B-$20.3B >BDX

2. Mai 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 2Q Net $537M >BDX

2. Mai 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 2Q Adj EPS $3.17 >BDX

2. Mai 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 2Q EPS $1.85 >BDX

2. Mai 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 2Q Rev $5B >BDX

Peer-Vergleich

Kursveränderung

Becton Dickinson and Co Prognose

Kursziel

By TipRanks

20.64% Vorteil

12-Monats-Prognose

Durchschnitt 280.7 USD  20.64%

Hoch 312 USD

Tief 255 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Becton Dickinson and Co – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

9

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

N/A / 236.38Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

8 / 365 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Becton Dickinson and Co

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through segments such as BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.